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Objectives. This observational study was set up to prospectively follow all bovine heterograft (ProColw) fistulas implanted
for hemodialysis access between 1998 and 2002.
Methods. ProColw was implanted if autogenous vein was not available or if patients presented with a history of failed,
infected or otherwise complicated ePTFE grafts and/or on immunosuppressive therapy. Fistula patency was the primary
outcome; secondary outcomes were clinical events and the rate of access revisions.
Results. Sixty-two ProColw grafts were implanted in 56 patients. The mean primary (PP) and secondary patency (SP) was
334 (SEM 57) and 528 (SEM 59) days, respectively. Coronary heart disease was associated with a significantly better SP
(OR 0.2, 95% CI 0.1–0.9) whilst diabetes mellitus was associated with a significantly worse SP (OR 0.2, 95% CI 0.1–0.9).
Reinterventions were performed at a mean rate of 1.23 (SEM 0.17) per fistula. The relative risk of access revision was
significantly higher in patients with diabetes mellitus (OR 9.2, 95% CI 2.3–37.2).
Conclusions. ProColw grafts, used for AV-fistulas, demonstrate acceptable patency rates in high-risk haemodialysis
patients. Diabetes mellitus jeopardizes the patency of these fistulas and is associated with a high revision rate.
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Introduction
Arteriovenous (AV) fistulas are the primary method of
long-term hemodialysis access. Autogenous radial- or
brachial-cephalic AV-fistulas are preferred types of
primary hemodialysis access due to excellent patency,
low complication rates and acceptable periinterven-
tional morbidity.1 – 10 If an autogenous fistula is
impractical, prosthetic or biological AV-grafts provide
an alternative approach.11 They offer a large surface
area, allowing simple cannulation, a short maturation
period and easy surgical handling.12 – 17
Despite these advantages, reduced primary and
secondary patency (PP/SP) rates, infections, and
pseudoaneurysms have been more frequently
reported with the commonly used polytetrafluoro-
ethylene (PTFE) grafts.1,7,18 Bovine heterografts have
also been used in the hope that they would be more
resistant to infection but their use was complicated by
rupture and life-threatening haemorrhage.19,20
Regardless of these complications, several retrospec-
tive series have found that the patency rates of these
grafts are comparable to PTFE.18,21 Current NKF-K/
DOQI guidelines do not favour the use of these
heterografts due to the aforementioned compli-
cations.11 However, ProColw, a denatured bovine
vessel-based bioartificial vascular conduit has recently
been introduced. Based on its high elastin to collagen
ratio, less anastomotic site compliance mismatch is
expected. This is thought to reduce para-anastomotic
subintimal hyperplasia.22
Although this graft was introduced with conflicting
results in infrainguinal reconstructions,23 Bacchini et al.
reported a series of 63 ePTFE and 22 ProColw implants
in 53 hemodialysis patients with superior PP and SP
compared to bovine vein graft.24
The objective of this prospective, non-randomized,
observational study was to demonstrate the feasibility,
patency and complication rate following ProColw
grafting between October 1998 and April 2002 in a
group of high-risk hemodialysis patients. Potential
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risk factors for an adverse outcome were also
evaluated.
Materials and Methods
Between October 1998 and April 2002, 319 de novo AV-
fistulas were created for haemodialysis access, of
which 187 were autogenous. Sixty-two ProColw grafts
were implanted in 56 patients. Redo ProColw grafts in
six patients were excluded from the evaluation.
ProColw was used in patients with insufficient vein
for autogenous fistula placement, as assessed by
Doppler screening, and who had a history of failed,
infected or otherwise complicated PTFE grafts, immu-
nosuppressive therapy, or diabetic patients with
infectious skin problems. The most peripheral site of
the non-dominant arm with sufficient arterial inflow,
and veins (.3 mm) was preferentially used. In 9% of
the patients, peripheral steal was anticipated and the
ProColw graft diameter was restricted to 4 mm. In all
other cases 6 mm implants were employed.
Under plexus anesthesia, atraumatic tunneling
connected the vessel sites. Grafts were prepared by
rinsing three times with sterile saline with 40 IU Na-
heparinate/ml and controlled for the correct flow
direction as instructed by the manufacturer. Anasto-
moses were performed with a monofilament running
suture (Prolenew 6-0).
Baseline data on the aetiology of renal failure, risk
factors and demographics, as well as the history of
renal replacement therapy including prior shunt
placement and informed consent were obtained before
implantation. Intraoperative data were recorded as
well as post-operative follow-up. Intraoperative blood
flow was measured using the transit time method
transmitting ultrasound created by two piezoelectric
crystals transvascular towards a reflector on the
opposite side of the vessel. Flow volume was
calculated by measuring transit times. We used the
CardioMed Flowmeter (Medi-Stim AS, Oslo, Norway)
with 6 mm probe according to Beldi et al.25
Outcome parameters are detailed according to the
reporting standards for vascular grafts suggested by
Sidawy et al.26 Patency and complication rates were
calculated starting at the date of implantation to either
renal transplantation, death or as defined by Sidawy
et al.26
All statistical analyses were performed using
SYSTAT Version 10 (SPSS Inc., Chicago, IL). (x2 testing,
Fig. 1. Survival probability with primary or secondary patency.
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Fig. 2. (A) Relative risk for a less than average primary patency. Indicated are odds ratios ^95% confidence intervals. (B)
Relative risk for a less than average secondary patency. Indicated are odds ratios ^95% confidence intervals. (C) Relative risk
for more than average access revisions. Indicated are odds ratios ^ 95% confidence intervals.
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Student’s t-test, and Cox proportional hazards
regression were applied. Univariate analysis of the
PP and SP of the first fistula used the Kaplan–Meier
technique, with date of fistula failure as the uncen-
sored end point. Logistic regression was used to
evaluate the statistical association between PP, SP,
rate of access revision and risk factors. The contri-
bution of covariates to explain the dependent variable
was assessed by means of a two-tailed likelihood ratio
test, with p , 0:05 considered significant. All data are
presented as absolute numbers, range, or mean and
SEM. Estimated relative risks (OR) and their 95%
confidence intervals (CI) are reported for all variables.
Results
Sixty-two Procolw fistulas were placed. The mean age
of the study population on referral was 63.5 (SEM 1.8)
years and 61% were men. The majority of these
patients (70%) was already on chronic intermittent
hemodialysis treatment while only 21% required
immediate de novo dialysis treatment, indicated by
the average time on dialysis (854, SEM 213 days). In
contrast, two patients with pre-emptive fistula place-
ment did not receive dialysis treatment during the
observation period as one died and one received a
successful renal transplant. The most common reasons
for end-stage renal failure were glomerulonephritis
(18%), vascular (16%) or diabetic nephropathy (14%),
vasculitis (9%) and cystic kidney disease (9%).
The follow-up ranged from 1 to 1401 days (mean
453, SEM 53). During the follow-up period, 13 patients
(23%) died, four (7%) received a renal transplant and
in one patient renal function recovered. The majority
of grafts were placed in a forearm location (71%),
preferably straight (59%) and the mean implantation
time was 148 (SEM 11) min. The long procedure time
was because almost all extremities used had had
former placement attempts. Kaplan–Meier life table
evaluation revealed a patency of 43 and 73% at 6
months and of 30 and 58% at 12 months for PP and SP,
respectively (Fig. 1). No interventional radiological
procedures to maintain patency were performed on
these fistulas. Risk factor analysis showed only a
minor increase of the calculated risk in fistulas patent
,6 months when compared to those patent .6
months: (7.3, SEM 0.43 vs. 6.8, SEM 0.37 and 7.50,
SEM 0.52 vs. 6.9 SEM 0.35 for PP and SP, respectively).
Several potential risk factors were evaluated for
their effect on fistula patency. PP was longest in the
presence of coronary heart disease independent of the
use of anti-platelet drugs or oral anticoagulants
although the relative risk analysis did not indicate a
significant benefit or disadvantage for any analyzed
factor with regard to PP (Fig. 2(A)). In contrast, with
regard to SP an independent risk reduction was
evident for patients with coronary heart disease (OR
0.2, 95% CI 0.1–0.9) and an independent risk pro-
gression for patients with diabetes mellitus (OR 0.2,
95% CI 0.1–0.9, Fig. 2(B)).
The mean fistula blood flow was .400 ml/min
(435, SEM 36). A flow rate of ,250 ml/min was
observed in eight patients with only modest reduction
in PP and SP27 and flow rates did not predict patency.
Antithrombotic therapy was continued in 79% of the
patients at discharge using acetylsalicylic acid, war-
farin or clopidogrel but there was no association with
continued patency.
The mean reintervention rate was 1.23 (SEM 0.17)
per fistula. At least one revision was required to
maintain the patency of 70% of the fistulae and 7%
needed four or more procedures. Most frequently,
fistulae required revisions for thrombosis (66%) or
venous stenosis (16%), less often due to other
conditions such as infections (10%) or peripheral
steal (8%). The relative risk of access revision was
significantly higher in patients with diabetes mellitus
(OR 9.2, 95% CI 2.3–37.2). Eighteen fistulae had to be
explanted for various reasons, such as recurrent
thrombosis (11%), stenosis (4%), steal (2%), granulo-
matous disease (2%), bleeding (2%), and recovered
renal function (2%). Thirteen infections occurred, six
(11%) required surgical excision of the fistula. There
was no difference in the frequency of infections with
respect to perisurgical antibiotic prophylaxis, which
had been given in 50% of the cases. In two patients, a
profound dilatation of the graft was observed but no
intervention was required.
Discussion
Vascular access problems remain the leading cause of
morbidity in the haemodialysis population despite
much interest in improving outcomes, such as the
DOQI guidelines.11 In this observational study, a high-
risk population of haemodialysis patients, indicated
by the high mortality rate during the follow-up period,
was monitored. In the absence of suitable autologous
veins, subcutaneous access placement of bioartificial
material, such as ProColw, is preferable to transcu-
taneous access.11 ProColw mimics the wall structure of
human vessels, and is believed to provide enhanced
resistance to infection compared to prosthetic grafts.
The decision to implant a ProColw graft was taken
because autogenous veins, as mandated by the DOQI
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guidelines, were absent and because the patients’
history did not favour a PTFE graft.
The primary intention was the creation of a forearm
fistula.28 This strategy may have led to the require-
ment of additional revisions and extended implan-
tation times, but may have saved future access sites.29
The patency of fistulas is determined by local and
systemic conditions, but also by patient-related events.
Grading of risk factors as proposed by Sidaway et al.26
did not allow discrimination between fistulae with
patency shorter and longer than 6 months, indicating
that this high-risk population of hemodialysis patients
was very homogenous. The longest primary patency
rates were observed in patients with coronary heart
disease, a finding that was not associated with the use
of an oral antithrombotic drug. The decision to start
antithrombotic therapy may have been biased by
complicated fistulas or a low intrasurgical blood flow
measurement, but it did not improve patency. The SP
was significantly better in patients with coronary heart
disease and worse in those with diabetes mellitus. As
suggested by the DOPPS study, calcium channel
blockers may improve PP and angiotensin converting
enzyme inhibitors (ACEI) SP.30 Calcium channel
blocker, ACEI, angiotensin II receptor blocker and b-
blocker are drugs given to patients with coronary heart
disease in end-stage renal disease.31 The risk reduction
for cardiovascular mortality and potentially for graft
failure is based on several beneficial effects, such as
blood pressure control, antiproliferative properties,
the reduction of the sympathetic tone or the pulse
wave velocity.32 – 34 Gibson et al.29 described an
increased risk of revision in diabetic patients, a finding
in line with our own observation. The majority of
revisions occurred due to early thrombosis within the
graft or at the anastomotic sites similar to an earlier
study comparing PVAG and ePTFE.28 A potential
explanation for this problem may be the local
thrombogenicity of the graft wall due to the continu-
ous release of glutaraldehyde.
It is of interest to compare the patency rates
obtained here with those in other types of fistulas,
such as ePTFE, polyurethanurea vascular access graft
or further heterografts. These comparisons are often
complicated by the heterogeneity of the patient
groups. Comparing ePTFE with PVAG, Glickman
et al.28 reported higher 12-month patency rates of
78–80% but their study included less men and less
patients with prior hemodialysis treatment. In con-
trast, SP rates in complicated transposition fistulas
have been described to be even lower than in our
study.35 In a recent review of the literature, SP rate for
PTFE accesses was 76% at 6 months i.e. very similar to
our findings.36
In conclusion, these data suggest that ProColw
grafts can be used for AV-fistulas with reasonable
results in high-risk patients without autogenous vein.
The favorable outcome in patients with coronary heart
disease deserves further evaluation to identify bene-
ficial factors, such as co-medication. In contrast,
diabetic patients have an increased risk of reduced
patency and more access revisions.
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